---
document_datetime: 2025-05-05 10:43:04
document_pages: 10
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/ecansya-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: ecansya-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 6.4135741
conversion_datetime: 2025-12-19 13:36:09.358893
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Ecansya

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                 | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                  |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/531/2 02404    | Periodic Safety Update EU Single assessment - capecitabine                                                                                            | 30/01/2025                          | 04/04/2025                                  | SmPC                             | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/531/202404. |
| IA/0041              | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites | 14/10/2024                          | n/a                                         |                                  |                                                                                                                                          |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | (excluding manufacturer for batch release)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |     |           |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------|
| IA/0040   | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 31/07/2024 | n/a | procedure |
| IB/0038/G | This was an application for a group of variations. B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate already approved manufacturer | 20/06/2024 | n/a | from an   |
| IA/0037   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 05/06/2024 | n/a |           |
| IA/0036   | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 13/05/2024 | n/a |           |

<div style=\"page-break-after: always\"></div>

| IA/0035/G   | application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)   | 16/01/2024   | n/a        |                 | This was an   |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|---------------|
| IB/0034     | B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation                                                                                                                                                                                                                                                                                                                 | 27/11/2023   | n/a        |                 |               |
| IB/0033     | B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation                                                                                                                                                                                                                                                                                                                                | 06/10/2023   | n/a        |                 |               |
| N/0032      | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                           | 24/08/2023   | 11/03/2024 | PL              |               |
| IA/0031     | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                              | 05/07/2023   | n/a        |                 |               |
|             | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch                                                                                                                                                                            | 06/03/2023   | 11/03/2024 | Annex II and PL | IA/0030/G     |

<div style=\"page-break-after: always\"></div>

|                   | control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                             |            |            |                 |                                                                                |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|--------------------------------------------------------------------------------|
| IAIN/0029         | B.III.1.a.3 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from a new manufacturer (replacement or addition)                                                                                                                                                                                                | 13/01/2023 | n/a        |                 |                                                                                |
| PSUSA/531/2 02104 | Periodic Safety Update EU Single assessment - capecitabine                                                                                                                                                                                                                                                                                                                                         | 02/12/2021 | n/a        |                 | PRAC Recommendation - maintenance                                              |
| IB/0027           | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                     | 02/04/2021 | 29/04/2022 | SmPC and PL     |                                                                                |
| IA/0026           | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                      | 16/03/2021 | 29/04/2022 | Annex II and PL |                                                                                |
| IA/0025           | B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size                                                                                                                                                                                                                                         | 17/07/2020 | n/a        |                 |                                                                                |
| A31/0023          | Pursuant to Article 31 of Directive 2001/83/EC, France requested on 13 March 2019 the opinion of the European Medicines Agency to assess the need to take action at EU level regarding the detection of DPD deficient patients (especially through genotyping and/or phenotyping) in patients treated with fluorouracil and related substances (capecitabine, tegafur and flucytosine). The Agency | 30/04/2020 | 03/07/2020 |                 | Please refer to the assessment report: Ecansya EMEA/H/A- 31/1481/C/002605/0023 |

<div style=\"page-break-after: always\"></div>

|                   | was requested to assess the impact thereof on the benefit-risk balance of fluorouracil and related substances containing products and to give its opinion on whether the marketing authorisation of these products should be maintained, varied, suspended or revoked.                                                                                                                                                                                                          |            |            |                                  |                                                                                                                                          |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0024           | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                    | 09/10/2019 | 03/07/2020 | SmPC, Annex II, Labelling and PL |                                                                                                                                          |
| PSUSA/531/2 01804 | Periodic Safety Update EU Single assessment - capecitabine                                                                                                                                                                                                                                                                                                                                                                                                                      | 31/01/2019 | 15/04/2019 | SmPC and PL                      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/531/201804. |
| IAIN/0022/G       | This was an application for a group of variations. B.III.1.a.1 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from an already approved manufacturer B.III.1.a.1 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from an already approved manufacturer B.III.1.a.3 - Submission of a new/updated or | 10/12/2018 | n/a        |                                  |                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

|                   | relevant Ph. Eur. Monograph - New certificate from a new manufacturer (replacement or addition)                                                                                                                                                              |            |            |                                  |                                                                                                                                                                                                                                                                       |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0021           | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 02/10/2018 | 15/04/2019 | SmPC and PL                      |                                                                                                                                                                                                                                                                       |
| R/0018            | Renewal of the marketing authorisation.                                                                                                                                                                                                                      | 13/10/2016 | 09/12/2016 | SmPC, Labelling and PL           | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Ecansya in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| IB/0019           | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 20/09/2016 | 09/12/2016 | SmPC, Labelling and PL           |                                                                                                                                                                                                                                                                       |
| IB/0017           | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 02/03/2016 | 31/03/2016 | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                                                       |
| PSUSA/531/2 01504 | Periodic Safety Update EU Single assessment - capecitabine                                                                                                                                                                                                   | 03/12/2015 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| IA/0016           | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                    | 21/09/2015   | n/a        |                        |                                   |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-----------------------------------|
| IAIN/0013         | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                         | 12/06/2015   | n/a        |                        |                                   |
| IB/0014           | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                            | 10/06/2015   | 31/03/2016 | SmPC and PL            |                                   |
| PSUSA/531/2 01404 | Periodic Safety Update EU Single assessment - capecitabine                                                                                                                                                                                                                                              | 04/12/2014   | n/a        |                        | PRAC Recommendation - maintenance |
| IA/0011           | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                        | 25/07/2014   | n/a        |                        |                                   |
| IB/0010/G         | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by | 03/04/2014   | 13/04/2015 | SmPC, Labelling and PL |                                   |

<div style=\"page-break-after: always\"></div>

|         | the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by   |            |            |                       | the   |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-------|
| IA/0009 | B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 26/03/2014 | n/a        |                       |       |
| IA/0008 | B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 25/09/2013 | n/a        |                       |       |
| IB/0007 | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 24/09/2013 | 15/11/2013 | SmPC, Annex II and PL |       |

<div style=\"page-break-after: always\"></div>

|           | - Implementation of change(s) for which NO additional data is required to be submitted by MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |            |             | product new the    |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------|
| IB/0006/G | This was an application for a group of variations. B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the currently approved batch size B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a material/reagent/intermediate for AS - Other | 26/07/2013 | n/a        |             | starting variation |
| IAIN/0005 | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 18/04/2013 | n/a        |             |                    |
| IB/0004   | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 08/04/2013 | 15/11/2013 | SmPC        |                    |
| IB/0003   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 02/04/2013 | 15/11/2013 | SmPC and PL |                    |

<div style=\"page-break-after: always\"></div>

|           | assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH   |            |            |                        |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| IAIN/0002 | A.2.a - Administrative change - Change in the (invented) name of the medicinal product for CAPs                                                   | 16/11/2012 | 15/11/2013 | SmPC, Labelling and PL |
| IAIN/0001 | B.II.b.2.b.1 - Change to batch release arrangements and quality control testing of the FP - Not including batch control/testing                   | 09/08/2012 | 25/10/2012 | Annex II and PL        |